• Home

Global Neurotechnology Market 2018-2022: Largest Segment is Currently Neuromodulation, Followed by Neuroprosthetics and Neurosensing

SOURCE Research and Markets

DUBLIN, Jan. 9, 2019 /PRNewswire/ --

The "The Market for Neurotechnology: 2018-2022" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The worldwide market for neurotechnology products will be $8.4 billion in 2018 and will reach $13.3 billion in 2022. The neurotechnology market is divided into four segments: neuroprosthetics, neuromodulation, neurorehabilitation, and neurosensing.

The Market for Neurotechnology: 2018-2022 covers in detail all the key public companies and the most significant emerging and more established non-public firms in the industry. The report also features in-depth profiles of major research institutions in the U.S. and abroad involved with neurotechnology developments, and traces the commercial activity that is emerging from each.

This market research report is the most comprehensive and up-to-date publication available covering the neurotechnology industry. The report takes an in-depth look at the technology, markets, competitors, and growth rates in four key segments of the neurotechnology industry in the years 2018 through 2022. It forecasts U.S. and worldwide revenue, compound annual growth rates, and competitor market shares for several key product categories making up the neuroprosthetics, neuromodulation, neurorehabilitation, and neurosensing segments of the industry.

The report not only looks at future financial projections, it covers likely technology trends and product developments that will impact the neurotechnology industry in the years ahead, such as:

  • Nanowire brain implants guided into position through the cerebral vasculature.
  • Optical stimulation devices that solve many of the problems associated with electrical charge buildup.
  • Microfluidic interfaces that combine electrical stimulation and drug delivery.

The Market for Neurotechnology: 2018-2022 examines each of the neurological diseases and disorders that represent a significant market potential for neurotechnology products, including established markets like Parkinson's disease, chronic pain, and urinary incontinence, as well as emerging markets such as bioelectronic medicine, obesity, migraine, sleep disorders, and psychiatric disorders. And it is the only report on the neurotechnology industry to forecast new product categories in neurorehabilitation and neurosensing such as brain analysis systems and neurorobotisc systems.

Market Projections

The largest segment of the market for neurotechnology is currently neuromodulation, followed by neuroprosthetics and neurosensing.

Within the neuroprosthetics product category, cochlear implants represent the largest and most mature product category. Two factors that are helping to drive the market for cochlear implants are the rapid growth of implants in children, and the expansion of the market beyond profoundly deaf individuals to severely hearing impaired individuals. Many of the candidates for cochlear implants in this latter category are seniors with hearing loss that can no longer be improved with hearing aids.


Neurotechnology has grown and matured as an industry as a result of advances in several fields of science and technology, including neuroscience, electrical stimulation, biomaterials, and microelectronics. MEMS technology will have a positive impact on the development of neurotechnology devices.

Neurotechnology is currently in use or under study for the treatment of a number of different medical disorders and diseases. These include spinal cord injury, deafness, blindness, stroke, urinary incontinence, epilepsy, chronic pain, neurological disorders, and psychiatric disorders.

Neurotechnology products and services will experience considerable growth in the worldwide healthcare market in large part because of the continued growth and identification of neurological disorders and conditions. Many of these disorders and conditions will become more pronounced as demographic shifts in the aging of the population, as well as increased life expectancy and demand for a higher quality of life by senior citizens, exert their effects.

As society has become more aware of the prevalence of specific neurological and neuropsychiatric disorders such as chronic pain, depression, dyslexia, and autism, business and government leaders have become more aware of the costs of these conditions to society in terms of lost productivity, treatment, and diminished quality of life. These factors will all contribute to the growth of neurotechnological treatments and therapies for neurological disorders.

Also, successful neuroprosthetics have been shown to be cost-effective because of the reduction in ongoing costs for healthcare and assistive services. Some studies have shown that these devices pay for themselves with five to seven years.

The neurotechnology industry depends heavily on the readiness of private and public health insurance organizations to reimburse patients for the cost of the devices and the procedures associated with implanting, maintaining, and training the device.

The growth of neurotechnology devices also depends heavily on the degree to which clinicians and their patients are aware of their capabilities. Because it is new, neurotechnology has not yet achieved the degree of penetration in awareness of both physicians and patients who would be strong candidates.


One of the greatest opportunities for growth in the market for neuromodulation device is treatment of obesity. Other new and emerging applications for neurotechnology devices are migrain pain, depression, and cardiovascular disorders such as hypertension and angina pain.

The author believes that the increasing understanding of central neural mechanisms in disorders such as depression, Parkinson's disease, and stroke will lead to dramatic growth for new neurotechnology products.


The market for neurotechnology includes both established competitors and start-up firms. Among the main competitors in the neurotechnology industry are:

  • Neuroprosthetics: Cochlear Ltd., Advanced Bionics, Bioness, Second Sight, Otto Bock, and Med-El
  • Neuromodulation: Medtronic, Boston Scientific, Abbott, Nuvectra, LivaNova, and Nevro
  • Neurosensing: Natus Medical, Nihon-Kohden, and Philips.

Future Trends

Carbon nanotubes and other advances in nanotechnology will confer new capabilities on neuromodulation products. New polymeric biomaterials are promising to enhance the functionality of existing neural interfaces, which are largely based on metals.

Neural/silicon hybrid chips have the potential for dramatically expanding the rate and the quality of information exchange between a computer and human. These devices initially will have application as improved forms of electrodes built with intelligent microelectronic hardware rather than passive devices. Ultimately they offer the potential for greatly enhanced neural prostheses and brain-computer interfaces.

Key Topics Covered:

I. Executive Summary

  • Market Projections
  • Competitors and Market Share
  • Organization
  • Research Methodology

II. Diseases, Disorders, and Conditions

  • Blindness
  • Cerebral Palsy
  • Cognitive Disorders
  • Epilepsy
  • Hearing Conditions
  • Incontinence
  • Migraine
  • Movement Disorders
  • Chronic Pain
  • Psychiatric Disorders
  • Sleep Apnea
  • Spinal Cord Injury
  • Stroke
  • Traumatic Brain Injury
  • Non-Neurological Diseases and Disorders

III. Neurotechnology Markets

  • Market Segments
  • Market Size
  • Core Technologies
  • Industry Origins
  • Competitive Landscape
  • Government Approval
  • Reimbursement
  • Industry Outlook

IV. Neuroprosthetics Products

  • Auditory Prostheses
  • Visual Prostheses
  • Upper Extremity Neuroprosthetics
  • Lower Extremity Neuroprosthetics
  • Robotic Exoskeletons
  • Other Neuroprosthetics Products

V. Neuromodulation Products

  • Implanted Spinal Cord Stimulators
  • Implanted Brain Stimulators
  • Vagus Nerve Stimulators
  • Incontinence Stimulators
  • Peripheral Nerve Stimulators
  • Cranial Nerve Stimulators
  • Surface Pain Stimulators
  • Transcranial Magnetic Stimulators
  • Transcranial Electrical Stimulators
  • Bioelectronic Stimulators

VI. Neurorehabilitation Products

  • Muscle Stimulators
  • Neural Reeducation Systems
  • Therapeutic Neurorobotic Systems
  • FES Exercise Systems
  • Other Neurorehabilitation Products

VII. Neurosensing Products

  • Electrophysiological Sensing Systems
  • Magnetic Sensing Systems
  • Brain Analysis Systems
  • Brain Computer Interfaces
  • Peripheral Neural Sensors

VIII. Company Profiles

  • Abbott
  • Advanced Bionics Corp
  • Aleva Neurotherapeutics
  • AlterG
  • Autonomic Technologies
  • Axonics Modulation, Inc
  • Bioness Inc
  • Blackrock Microsystems
  • Boston Scientific Corp
  • BrainScope
  • Circuit Therapeutics Inc
  • Cleveland Medical Devices Inc
  • Cochlear Ltd
  • Cogentix Medical
  • CVRx, Inc
  • ElectroCore Medical, LLC
  • EndoStim, Inc
  • Great Lakes NeuroTechnologies Inc
  • Halyard Health
  • Hanger Inc
  • Hocoma AG
  • ImThera Medical (Part of LivaNova)
  • Inspire Medical Systems
  • LivaNova plc
  • Mainstay Medical
  • Med-El
  • Medtronic plc
  • MicroTransponder Inc
  • Natus Medical Inc
  • NDI Medical Inc
  • NeuroMetrix Inc
  • Neuronetics
  • NeuroPace Inc
  • Neuros Medical
  • NeuroSigma Inc
  • Nevro Corp
  • Nexeon Medsystems, Inc
  • Nihon Kohden Corp
  • Nuvectra Corp
  • Ossur hf
  • Otto Bock Health Care GmbH
  • ReShape Lifesciences Inc
  • Restorative Therapies Inc
  • Royal Philips
  • Saluda Medical
  • Second Sight Medical Products
  • SetPoint Medical
  • SPR Therapeutics
  • Stimwave LLC
  • Zynex Medical

IX. Research Institution Profiles

  • Aalborg University
  • University of Alberta
  • Alfred Mann Foundation
  • Arizona State University
  • Battelle
  • Baylor College of Medicine
  • Brown University
  • University of California Davis
  • University of California, Irvine
  • University of California, Los Angeles
  • University of California, Santa Barbara
  • University of California, San Francisco
  • Caltech
  • Case Western Reserve University
  • University of Chicago
  • Cleveland Clinic
  • Clinatec
  • Cornell University
  • Drexel University
  • Duke University
  • Feinstein Institute for Medical Research
  • Florida International University
  • University of Freiburg
  • Georgia Tech
  • University of Glasgow
  • Illinois Institute of Technology
  • Johns Hopkins University
  • University of Ljubljana
  • Max Planck Florida Institute for Neuroscience
  • McMaster University
  • University of Miami
  • University of Michigan
  • Mount Sinai Health System
  • New York University
  • Northwestern University
  • University of Pennsylvania
  • University of Pittsburgh
  • Queensland Brain Institute
  • Rehabilitation Institute of Chicago
  • University of Southern California
  • University of Texas at Arlington
  • University of Texas at Dallas
  • Univeristy of Texas Southwestern
  • University of Toronto
  • University of Utah
  • UMC Utrecht
  • West Virginia University
  • University of Zurich

X. Funding Sources

  • U.S. Government
  • State Governments
  • Foreign Governments
  • Private Organizations
  • Venture Capital Funding
  • VC Investors in Neurotechnology
  • Novel Funding Sources

XI. Future Directions

  • Nanotech Devices
  • Optical Neurotechnology
  • Electrode Design
  • Neural/Silicon Hybrid Chips
  • Sensing Neuroprosthetics
  • Neurosurgical Tools
  • Appendix A: Company Listings

For more information about this report visit https://www.researchandmarkets.com/research/658b56/global?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/global-neurotechnology-market-2018-2022-largest-segment-is-currently-neuromodulation-followed-by-neuroprosthetics-and-neurosensing-300775578.html

©2017 PR Newswire. All Rights Reserved.

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com